Attorney Docket No.: 2183-6028US

1. (Original) A method of directing integration of a nucleic acid of interest to a predetermined site, wherein said nucleic acid has homology at or around said predetermined site, in a eukaryote with a preference for nonhomologous recombination, said method comprising:

steering an integration pathway towards homologous recombination.

- 2. (Original) The method of directing nucleic acid integration according to claim 1, further comprising: providing a mutant of a component involved in nonhomologous recombination.
- 3. (Amended) The method of directing nucleic acid integration according to claim 1, further comprising: inhibiting a component involved in nonhomologous recombination.
- 4. (Amended) The method according to claim 2 wherein said component involved in nonhomologous recombination comprises ku70, rad50, mre11, xrs2, lig4 or sir4.
- 5. (Amended) The method of directing integration of a nucleic acid of interest to a predetermined site according to claim 1, wherein said nucleic acid of interest is essentially replacing a sequence within said eukaryote.
- 6. (Original) The method of directing integration of a nucleic acid of interest to a predetermined site according to claim 5, wherein said component involved in nonhomologous recombination comprises *rad50* or *xrs2*.
- 7. (Original) A method of directing integration of a nucleic acid of interest to a subtelomeric region, a telomeric region, or a subtelomeric region and telomeric region in a eukaryote with a preference for nonhomologous recombination by providing a mutant of a component involved in nonhomologous recombination.
 - 8. (Original) A method of directing integration of a nucleic acid of interest to a

Attorney Docket No.: 2183-6028US

subtelomeric region, a telomeric region, or a subtelomeric region and telomeric region in a eukaryote with a preference for nonhomologous recombination, comprising inhibiting a component involved in nonhomologous recombination.

- 9. (Amended) The method of directing integration according to claim 7 wherein said component involved in nonhomologous recombination comprises *rad50*, *mre11* or *xrs2*.
- 10. (Amended) The method according to claim 1 wherein said eukaryote is selected from the group consisting of yeast, fungus, and an animal.
- 11. (Amended) The method according to claim 1, wherein said nucleic acid of interest is delivered to a cell of said eukaryote by *Agrobacterium*.
- 12. (Amended) The method according to claim 1 comprising transiently inhibiting integration via nonhomologous recombination.
- 13. (Original) The method according claim 12 wherein said transiently inhibiting is provided by an *Agrobacterium* Vir-fusion protein capable of inhibiting a component involved in nonhomologous recombination.
- 14. (Original) The method of directing integration according to claim 13 wherein said *Agrobacterium* Vir-fusion protein comprises VirF or VirE2.
- 15. (Amended) The method according to claim 13 wherein said component involved in nonhomologous recombination comprises ku70, rad50, mre11, xrs2, lig4 or sir4.
- 16. (Amended) The method according to claim 1 wherein said nucleic acid of interest comprises an inactive gene to replace an active gene.

Attorney Docket No.: 2183-6028US

- 17. (Amended) The method according to claim 1, wherein said nucleic acid of interest comprises an active gene to replace an inactive gene.
- 18. (Amended) The method according to claim 1, wherein said nucleic acid of interest encodes a therapeutic proteinaceous substance.
- 19. (Amended) The method according to claim 1, wherein said nucleic acid of interest encodes a substance conferring resistance for an antibiotic substance to a cell.
- 20. (Amended) The method according to claim 1, wherein said nucleic acid of interest confers a desired property to said eukaryote.
- 21. (Amended) The method according to claim 1 wherein said nucleic acid of interest is part of a gene delivery vehicle.
 - 22. (Canceled herein).

Please add the following new claim:

23. The method of directing integration according to claim 8 wherein said component involved in nonhomologous recombination comprises *rad50*, *mre11* or *xrs2*.